MDS 2022 | COMT inhibitors for Parkinson’s disease: clinical updates

Catechol-O-methyltransferase (COMT) inhibitors are used for the management of motor complications associated with Parkinson’s disease (PD). Margherita Fabbri, MD, PhD, University of Toulouse, Toulouse, France, comments on the clinical use of entacapone, tolcapone and opicapone, the three approved COMT inhibitors. Entacapone and opicapone are first-line therapies, while tolcapone is considered a second-line agent. Regarding their use in the early stage of the disease, it is not recommended to use entacapone. Several trials are evaluating the efficacy of opicapone, the only drug with a once-daily dosing regimen, in patients without motor fluctuations. This interview took place at the 2022 International Congress of Parkinson’s disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.